Chronic Kidney Disease (CKD) has been increasingly recognized as a condition that may represent accelerated kidney aging, with cellular senescence playing a pivotal role in its onset and progression. Research indicates that senescent cells, which accumulate with age and contribute to chronic inflammation, may be a significant factor in the pathology of CKD. This open-access paper reviews the parallels between kidney aging and CKD, highlighting that both conditions exhibit similar structural and functional declines, such as nephron reduction, glomerulosclerosis, and increased fibrosis.

The findings underscore the therapeutic potential of targeting cellular senescence in CKD. As aging kidneys are already predisposed to injury and inflammation, the accumulation of senescent cells exacerbates these issues, leading to a decline in renal function. Recent studies have identified specific senescence-associated pathways, such as TNF, NF-κB, and MAPK signaling, that correlate with worse renal outcomes. This suggests that CKD could be stratified into senescence-based endotypes (sendotypes), allowing for precision medicine approaches where therapies could be tailored to target specific senescence-related pathways in patient subgroups.

The implication for the field is significant: the development of senotherapeutics—drugs that selectively eliminate or modulate the behavior of senescent cells—could provide a novel strategy for managing CKD and potentially mitigating age-related kidney dysfunction. As initial clinical trials using senolytic drugs have already begun in diabetic kidney disease, this research paradigm shift could accelerate drug development timelines and offer new hope for improving healthspan in aging populations. Understanding the intricate relationship between senescence and kidney pathology may pave the way for innovative interventions in both CKD and age-related renal decline.

Source: fightaging.org